Form 4: MBX Biosciences Director Acquires Stock Options
SEC Form 4 Filing
James M. Cornelius, a director of MBX Biosciences, acquired stock options for 15,963 shares on September 12, 2024.
Summary
- On September 12, 2024, James M. Cornelius, a director of MBX Biosciences, acquired stock options for 15,963 shares.
- The exercise price of these options is $16.
- The options vest over time, with 25% becoming exercisable on September 12, 2025, and the remaining 75% vesting in 36 equal monthly installments thereafter, contingent upon continued service.
- Following the transaction, Cornelius directly owns 15,963 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition by a director.
Future Outlook
The vesting schedule indicates a long-term alignment of the director's interests with the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for maintaining investor confidence.
Stakeholder Impact
- The acquisition of stock options by a director can signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of transaction: Director acquired stock options. |
| 09/12/2025 | 25% of the stock options vest and become exercisable. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/13/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.